Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating today. Ami Fadia has given his Hold rating ...

Imaging in neurosurgery patients showed how the brain's glymphatic system clears waste. ( PNAS) Investigational apitegromab ...

After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...

Talkiatry to offer new resources and expand access to care for women experiencing postpartum mental health challenges by virtually connecting them with a provider from the comfort of their own home ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...

U.S. stock index futures on Tuesday pointed to a slightly higher open, as market participants looked ahead to key inflation ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage said it will continue to test dalzanemdor as a treatment for Huntington's disease and expects to report its mid-stage ...